Patents Assigned to Institute of Cancer Research
-
Patent number: 11993589Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.Type: GrantFiled: December 7, 2022Date of Patent: May 28, 2024Assignee: Institute For Cancer ResearchInventors: Wafik S. El-Deiry, Xiaobing Tian
-
Patent number: 11993653Abstract: Provided are antibodies that specifically bind to CTLA-4 and/or PD-1 and antagonize CTLA-4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies either alone or in combination.Type: GrantFiled: June 7, 2019Date of Patent: May 28, 2024Assignees: AGENUS INC., Ludwig Institute for Cancer Research Ltd., Memorial Sloan Kettering Cancer CenterInventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Roberta Zappasodi, Rikke Baek Holmgaard, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
-
Patent number: 11987843Abstract: This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5-hydroxymethylcytosine, 5-carboxylcytosine and 5-formylcytosine.Type: GrantFiled: March 7, 2022Date of Patent: May 21, 2024Assignee: Ludwig Institute for Cancer Research, LTDInventors: Chunxiao Song, Yibin Liu
-
Publication number: 20240158397Abstract: Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are otherwise delivered to the brain.Type: ApplicationFiled: May 26, 2023Publication date: May 16, 2024Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: Gabriela Chiosis, Huazhong He, Danuta Zatorska
-
Patent number: 11970469Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.Type: GrantFiled: June 3, 2019Date of Patent: April 30, 2024Assignee: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITALInventors: Terrence Rabbitts, Camilo Quevedo, Carole Bataille
-
Publication number: 20240131070Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.Type: ApplicationFiled: December 11, 2023Publication date: April 25, 2024Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.Inventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas, Paul Balderes, Ivo C. Lorenz, Zeda Zhang
-
Publication number: 20240123069Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.Type: ApplicationFiled: December 11, 2023Publication date: April 18, 2024Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas, Zeda Zhang
-
Patent number: 11959136Abstract: This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5-hydroxymethylcytosine, 5-carboxylcytosine and 5-formylcytosine.Type: GrantFiled: March 7, 2022Date of Patent: April 16, 2024Assignee: Ludwig Institute for Cancer Research, LTDInventors: Chunxiao Song, Yibin Liu
-
Patent number: 11957751Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: February 12, 2021Date of Patent: April 16, 2024Assignee: Ludwig Institute for Cancer Research, Ltd.Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Publication number: 20240117066Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to uPAR and methods of using such antibodies or antigen-binding fragments thereof same.Type: ApplicationFiled: December 11, 2023Publication date: April 11, 2024Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute For Cancer Research, Memorial Hospital For Cancer and Allied DiseasesInventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas
-
Patent number: 11946043Abstract: The present disclosure provides methods for selectively tagging 5-methylcytosine in a DNA sample and using this approach for genome-wide profiling of 5-methylcytosine in a low input DNA sample such as circulating cell-free DNA.Type: GrantFiled: September 11, 2018Date of Patent: April 2, 2024Assignee: Ludwig Institute for Cancer Research LtdInventors: Chunxiao Song, Paulina Siejka
-
Patent number: 11944319Abstract: The present disclosure provides surgical clamps. The clamp has a body with a mouth that opens and closes to permit the body to encircle a bundle of tissue containing a blood vessel which a surgeon wishes to occlude. The clamp also has an articulating arm that rotates on a hinge and passes through apertures of the clamp body. The apertures and/or the articulating arm include ratchet components that permit the surgeon to apply dynamic adjustable tensioning to the tissue and vessel in real time. This dynamic tension permits a surgeon to ensure a specific reduction of blood flow through the vessel.Type: GrantFiled: February 12, 2019Date of Patent: April 2, 2024Assignee: Institute For Cancer ResearchInventors: Benjamin T. Ristau, Robert G. Uzzo
-
Publication number: 20240050486Abstract: The present disclosure provides methods for generating cortical excitatory neurons, cortical excitatory neurons generated by such methods, and composition comprising such cells. The present disclosure also provides uses of the cortical excitatory neurons and composition comprising thereof for preventing and/or treating neurodegenerative disorders.Type: ApplicationFiled: July 7, 2023Publication date: February 15, 2024Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied DiseasesInventors: Lorenz Studer, Gabriele CICERI
-
Publication number: 20240050385Abstract: The present disclosure relates to the use of iron chelation to prevent and/or treat leptomeningeal metastasis. In certain embodiments, the present disclosure provides methods for the prevention and/or treatment of leptomeningeal metastasis that include the administration of an iron chelator to a subject. The present disclosure further provides kits for performing such methods.Type: ApplicationFiled: January 17, 2023Publication date: February 15, 2024Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Adrienne Boire, Yudan Chi
-
Publication number: 20240052420Abstract: The present invention provides a method for predicting whether a human subject having breast cancer will be resistant to, or sensitive to, therapy with a cyclin-dependent kinase (CDK) inhibitor, the method comprising: a) measuring the gene expression in a sample obtained from the breast tumour of the patient to obtain a sample gene expression profile of at least the following modules: (i) a luminal vs.Type: ApplicationFiled: September 24, 2021Publication date: February 15, 2024Applicants: The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology Limited, Breast Cancer NowInventors: Mitchell Dowsett, Eugene Francis Schuster, Chon U Maggie Cheang
-
Patent number: 11897962Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: August 21, 2020Date of Patent: February 13, 2024Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Publication number: 20240016957Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fr receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.Type: ApplicationFiled: July 25, 2023Publication date: January 18, 2024Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer CenterInventor: Kerry S. Campbell
-
Publication number: 20240018600Abstract: There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.Type: ApplicationFiled: November 14, 2022Publication date: January 18, 2024Applicants: Ontario Institute for Cancer Research (OICR), UNIVERSITY HEALTH NETWORKInventors: Julia A. HOPKINS, Paul Boutros, Robert G. BRISTOW
-
Patent number: 11859183Abstract: The present disclosure provides miRNA mimics targeting CDK4 and/or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.Type: GrantFiled: May 10, 2021Date of Patent: January 2, 2024Assignee: Institute For Cancer ResearchInventors: Amriti R. Lulla, Wafik S. El-Deiry
-
Publication number: 20230414660Abstract: The present disclosure relates to novel PD-1 decoy variants, compositions, and methods to confer and/or increase immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific genetically-modified subsets of lymphocytes.Type: ApplicationFiled: November 12, 2021Publication date: December 28, 2023Applicants: Ludwig Institute for Cancer Research Ltd, Centre Hospitalier Universitaire Vaudois, University of LausanneInventors: George Coukos, Melita Irving, Vincent Zoete